CUE
Cue Biopharma Inc

1,446
Mkt Cap
$29.21M
Volume
379,662.00
52W High
$1.54
52W Low
$0.2302
PE Ratio
-0.70
CUE Fundamentals
Price
$0.3201
Prev Close
$0.3161
Open
$0.3146
50D MA
$0.3941
Beta
1.28
Avg. Volume
1.96M
EPS (Annual)
-$0.7221
P/B
1.88
Rev/Employee
$226,512.20
Loading...
Loading...
News
all
press releases
Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Lags Revenue Estimates
Cue Biopharma (CUE) delivered earnings and revenue surprises of +30.00% and -14.04%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
More News
News Placeholder
CervoMed Inc. (CRVO) Reports Q3 Loss, Misses Revenue Estimates
CERVOMED INC (CRVO) delivered earnings and revenue surprises of -23.53% and -69.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Puma Biotech (PBYI) Q3 Earnings and Revenues Top Estimates
Puma Biotech (PBYI) delivered earnings and revenue surprises of +133.33% and +12.67%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Beats Revenue Estimates
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +6.25% and +38.15%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Insmed (INSM) Reports Q3 Loss, Beats Revenue Estimates
Insmed (INSM) delivered earnings and revenue surprises of -32.58% and +24.16%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates
Cue Biopharma (CUE) delivered earnings and revenue surprises of +30.77% and +47.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6mo ago
News Placeholder
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates
YmAbs Therapeutics (YMAB) delivered earnings and revenue surprises of +74.07% and +5.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6mo ago
News Placeholder
scPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Lags Revenue Estimates
scPharmaceuticals (SCPH) delivered earnings and revenue surprises of -13.33% and -2.19%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6mo ago
News Placeholder
Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates
Zacks·9mo ago
<
...
1
>

Latest CUE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.